Last reviewed: July 18, 2026
Last updated: July 18, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Mounjaro (tirzepatide) received FDA approval in 2022 as a treatment for type 2 diabetes, but clinical trials revealed an unexpected benefit: patients lost an average of 12% to 22% of their body weight. While the medication's primary indication remains blood sugar control, its dual-hormone mechanism has made it increasingly popular for weight management both on-label and off-label.
What Is Mounjaro and How Does It Function?
Mounjaro contains tirzepatide, a once-weekly injectable medication that activates two hormone receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). By stimulating both pathways simultaneously, tirzepatide creates a more comprehensive effect on appetite regulation, gastric emptying, and metabolic rate than medications targeting a single pathway alone.
The GLP-1 pathway slows stomach movement and increases feelings of fullness after eating, while the GIP pathway influences energy expenditure and glucose metabolism. This dual-action design explains why tirzepatide users often experience significant reductions in hunger and calorie intake without the extreme fatigue or metabolic suppression seen with older weight loss approaches.
Clinical Evidence for Tirzepatide Weight Loss Outcomes
The SURMOUNT trials, which specifically evaluated tirzepatide for weight management in non-diabetic adults, demonstrated dose-dependent weight loss ranging from 16% to 22% of baseline body weight over 72 weeks. Participants receiving the highest dose lost approximately 52 pounds on average, with most weight loss occurring in the first 24 weeks of treatment followed by continued gradual decline.
These results exceed outcomes from earlier GLP-1-only medications like semaglutide, which typically produce 10% to 15% weight loss in comparable populations. The IIP mechanism also appears to preserve lean muscle mass during weight loss and may improve cardiometabolic markers including blood pressure and cholesterol levels independent of weight reduction alone.
Tirzepatide vs. Semaglutide: Understanding Key Differences
Both tirzepatide and semaglutide are injectable GLP-1 class medications, but tirzepatide's dual-receptor activation produces stronger appetite suppression and faster initial weight loss in clinical studies. Semaglutide works through GLP-1 alone, making it a reasonable option for patients who may not tolerate or respond optimally to dual-pathway stimulation.
Individual genetic factors influence which medication class produces the best results for a given patient. PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, and related metabolic pathways to identify whether a patient's biology favors GLP-1 monotherapy, dual GIP-GLP-1 activation, or alternative peptide protocols. This testing guides treatment selection and dose optimization from the first injection.
Personalized Tirzepatide Options and Accessibility Through PlexusDx
PlexusDx offers compounded tirzepatide injections from licensed 503A pharmacies starting at $289 per month, with no insurance requirement and HSA/FSA eligibility. Patients receive medical supervision from licensed providers and access to dose adjustment protocols designed to maximize results while minimizing side effects.
For individuals seeking additional metabolic support, PlexusDx also provides GLP-Squared Injection (a dual-compound combining semaglutide and tirzepatide in one formulation) and the Precision Peptide Genetic Test ($99 add-on) to identify genetic predictors of optimal peptide response. All medications are shipped discreetly to patients' homes, with most orders arriving within 2–3 business days across all 50 states.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Mounjaro approved by the FDA specifically for weight loss?
Mounjaro's FDA approval is for type 2 diabetes management; however, the drug tirzepatide itself is being studied in weight loss trials, and prescribers may recommend it off-label for weight management in appropriate patients. PlexusDx compounded tirzepatide follows the same active ingredient formulation and is provided under medical supervision for personalized dosing.
How quickly do people typically see weight loss results with tirzepatide?
Clinical trial data shows most participants experience noticeable appetite reduction within 2–4 weeks of starting tirzepatide. Measurable weight loss typically appears by week 8, with the steepest decline occurring between weeks 12 and 24; continued gradual loss continues through 52+ weeks of consistent use.
What is the cost of tirzepatide through PlexusDx, and does it vary by dose?
PlexusDx tirzepatide injections start at $289/mo (or $249/mo on the 6-month plan) with a flat-rate pricing model—your dose may need to go up, but your price won't. The medication is HSA/FSA eligible and requires no insurance, making it accessible to patients regardless of coverage status.
What are the most common side effects of tirzepatide for weight loss?
Nausea, vomiting, and constipation are the most frequently reported side effects, typically appearing in the first 1–2 weeks and often resolving within 2–4 weeks. Slow dose escalation and careful monitoring by PlexusDx providers help minimize discomfort and improve medication tolerance.
How can genetic testing help me choose between tirzepatide and other GLP-1 options?
No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Mounjaro Pen Essentials: How Many Shots Inside and What to Know
Can You Drink Alcohol While Taking Mounjaro for Weight Loss?